ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO007

Human Recombinant α-1-Microglobulin Protects Against AKI in Rat Models of Ischemia-Reperfusion Injury (IRI)

Session Information

Category: Acute Kidney Injury

  • 103 AKI: Mechanisms


  • Gram, Magnus, A1M Pharma AB, Lund, Sweden
  • Larsson, Tobias E., A1M Pharma, Lund, Sweden
  • Campos-bilderback, Silvia B., Indiana University, Indianapolis, Indiana, United States
  • Sandoval, Ruben M., Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Molitoris, Bruce A., Indiana University School of Medicine, Indianapolis, Indiana, United States

Acute kidney injury (AKI) is a global health concern associated with high morbidity, mortality, and progressive chronic kidney disease (CKD). RMC-035, a recombinant human α1-microglobulin (A1M), has demonstrated protective antioxidant effects in several injury models. The principal mechanisms of RMC-035 are heme binding, reductase activity, radical scavenging and protection of mitochondria. RMC-035 is being developed for the prevention of cardiac surgery associated-AKI, and are currently evaluated in a Phase 1 study. We present preclinical data for RMC-035, supporting its protective effect in ischemic AKI and AKI on a CKD background.


RMC-035 (0-5 mg/kg, i.v.) was administered at various time-points and doses prior and/or post renal ischemia in rats exposed to unilateral nephrectomy followed by a 30 minute pedicle clamp ischemia. AKI was evaluated at 1-5 days post injury by serum creatinine (sCr), BUN and 24 hr urinary creatinine clearances (CrCl). Furthermore, RMC-035 (2 mg/kg, i.v.) was administered prior to and post renal clamp ischemia in rats previously subjected to unilateral and renal ischemia (“AKI on CKD model”). Texas Red-x labeled RMC-035 (TR-RMC-035) trafficking and handling by proximal tubule cells (PTC) was studied via intravital imaging.


RMC-035 caused a dose-dependent decrease in AKI measured as reduced proteinuria, sCr and BUN levels, and improved 24 hr CrCl, in rats subjected to a single renal IRI episode. RMC-035 given prior and post renal IRI was more effective for protection vs a single dose given either before or after IRI. In a CKD model with two successive episodes of AKI over 28 days, RMC-035 given at the second IRI episode significantly reduced renal injury by sCr and CrCl. TR-RMC-035 was rapidly filtered and bound to the apical brush border in PTC. Accumulation of RMC-035, tubular-vesicular extensions and vesicular trafficking was seen from 30 minutes through 24 hr post infusion. Cytosolic release was seen as early as 70 minutes.


RMC-035 demonstrates dose-dependent protective effects against AKI in multiple IRI models including AKI on CKD, had a prolonged PTC half-life including release into the cytosol, thus being a novel and promising therapeutic candidate for the treatment of cardiac surgery associated-AKI.


  • NIDDK Support